Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe N. Amaria, Amir A. Jazaeri, Karen H. Lu et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 54
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signalingSamantha M. Fix, Amir A. Jazaeri, Marie‐Andrée Forget et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 44
Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers.Rodabe N. Amaria, Amir A. Jazaeri, Chantale Bernatchez et al.|Journal of Clinical Oncology|2019Cited by 6
Pulmonary resection for tissue harvest in adoptive tumor‐infiltrating lymphocyte therapy: Safety and feasibilityErin M. Corsini, Mara B. Antonoff, K. G. Mitchell et al.|Journal of Surgical Oncology|2021Cited by 6
Efficacy and safety of autologous expanded tumor infiltrating lymphocytes (TILs) in multiple solid tumors.Rodabe N. Amaria, Amir A. Jazaeri, David Vining et al.|Journal of Clinical Oncology|2022Cited by 3